Federation des caisses Desjardins du Quebec’s DiaMedica Therapeutics DMAC Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-230	Closed	-$679	–	2601
2024 Q2	$679	Hold	230	–	–	﹤0.01%	2229
2024 Q1	$637	Hold	230	–	–	﹤0.01%	2219
2023 Q4	$653	Hold	230	–	–	﹤0.01%	2182
2023 Q3	$593	Hold	230	–	–	﹤0.01%	2199
2023 Q2	$994	Hold	230	–	–	﹤0.01%	2132
2023 Q1	$352	Hold	230	–	–	﹤0.01%	2235
2022 Q4	$363	Hold	230	–	–	﹤0.01%	2371
2022 Q3	$285	Hold	230	–	–	﹤0.01%	2430
2022 Q2	$465	Hold	230	–	–	﹤0.01%	2446
2022 Q1	$575	Hold	230	–	–	﹤0.01%	2472
2021 Q4	$858	Hold	230	–	–	﹤0.01%	2431
2021 Q3	$922	Hold	230	–	–	﹤0.01%	2463
2021 Q2	$1.02K	Sell	230 -5,800	-96%	-$47.6K	﹤0.01%	2434
2021 Q1	$55.2K	Hold	6,030	–	–	﹤0.01%	1520
2020 Q4	$61.1K	Buy	6,030 +230	+4%	+$1.26K	﹤0.01%	1424
2020 Q3	$24.6K	Hold	5,800	–	–	﹤0.01%	1435
2020 Q2	$40.2K	Hold	5,800	–	–	﹤0.01%	1269
2020 Q1	$16.2K	Hold	5,800	–	–	﹤0.01%	1542
2019 Q4	$28.1K	Buy	+5,800	New	+$18.1K	﹤0.01%	1656

Other funds holding DMAC

CLG

Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

PAPAIJV

Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's DMAC Position: Q3 2024 in Review

Federation des caisses Desjardins du Quebec sold out of DiaMedica Therapeutics (DMAC) in Q3 2024, closing a stake of 230 shares — an estimated $679 sold.

Federation des caisses Desjardins du Quebec first reported a position in DMAC in Q4 2019 and held it in 19 quarters. The position peaked at $61.1K in Q4 2020. 40 funds tracked by Wall St. Rank hold DMAC as of Q3 2024.

Federation des caisses Desjardins du Quebec reported no remaining DiaMedica Therapeutics position as of Q3 2024 after selling out during the quarter.
Federation des caisses Desjardins du Quebec sold 230 DiaMedica Therapeutics shares in Q3 2024, an estimated $679.
Federation des caisses Desjardins du Quebec first reported a position in DiaMedica Therapeutics in Q4 2019 and held it in 19 quarters.
Federation des caisses Desjardins du Quebec's DiaMedica Therapeutics position peaked at $61.1K in Q4 2020.
40 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q3 2024.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q3 2024, filed 13 Nov 2024.